CV. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

Compartir

Wanwisa Dejnirattisai, et al.

Recopilado por Carlos Cabrera Lozada. Miembro Correspondiente Nacional, ANM puesto 16. ORCID: 0000-0002-3133-5183. 13/12/2021

Abstract

In this report, we present live neutralisation titres against SARS-CoV-2 Omicron variant, compared with neutralisation against Victoria, Beta and Delta variants. Sera from day-28 post second-dose were obtained from participants in the Com-COV2 study who had received a two-dose COVID-19 vaccination schedule with either AstraZeneca (AZD1222) or Pfizer (BNT162b2) vaccines. There was a substantial fall in neutralisation titres in recipients of both AZD1222 and BNT162b2 primary courses, with evidence of some recipients failing to neutralise at all. This will likely lead to increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection, although there is currently no evidence of increased potential to cause severe disease, hospitalisation or death.

Deja un comentario

Tu dirección de correo electrónico no será publicada.

dieciocho − diecisiete =